{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:59:46Z","timestamp":1790686786323,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01696-4","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:32:51Z","timestamp":1787751171000},"page":"1463-1515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy. Part II: Cephalosporins"],"prefix":"10.1007","volume":"65","author":[{"given":"Femke A.","family":"Elzinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee R. M.","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline H.","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelmer R.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars C.","family":"Nijdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn N. Lub-de","family":"Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik L. J","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G. W.","family":"Kosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"11","key":"1696_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"G Pariente","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016;13(11):e1002160. https:\/\/doi.org\/10.1371\/journal.pmed.1002160. (PubMed PMID: 27802281).","journal-title":"PLoS Med"},{"issue":"6","key":"1696_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/cpt.1084","volume":"104","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Pfister M, van den Anker J, Eissing T. Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of Published Models. Clin Pharmacol Ther. 2018;104(6):1110\u201324. https:\/\/doi.org\/10.1002\/cpt.1084. (PubMed PMID: 29633257).","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1696_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/1060028018817935","volume":"53","author":"H Rac","year":"2019","unstructured":"Rac H, Gould AP, Eiland LS, Griffin B, McLaughlin M, Stover KR, et al. Common bacterial and viral infections: review of management in the pregnant patient. Ann Pharmacother. 2019;53(6):639\u201351. https:\/\/doi.org\/10.1177\/1060028018817935.","journal-title":"Ann Pharmacother"},{"key":"1696_CR4","unstructured":"Geneva: World Health Organization. WHO recommendation on prophylactic antibiotics for women undergoing caesarean section [Internet]. 2021 [cited 2026 Jan 12]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571491\/table\/fm-ch2.tab1\/. Accessed 12 Jan 2026."},{"key":"1696_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejps.2018.09.008","volume":"125","author":"JW Mouton","year":"2018","unstructured":"Mouton JW. Soup with or without meatballs: impact of nutritional factors on the MIC, kill-rates and growth-rates. Eur J Pharm Sci. 2018;125:23\u20137. https:\/\/doi.org\/10.1016\/j.ejps.2018.09.008.","journal-title":"Eur J Pharm Sci"},{"key":"1696_CR6","unstructured":"PRISMA [Internet]. [cited 2025 Jul 25]. https:\/\/www.prisma-statement.org. Accessed 25 Jul 2025."},{"issue":"2","key":"1696_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000097105","volume":"22","author":"N Papantoniou","year":"2007","unstructured":"Papantoniou N, Ismailos G, Daskalakis G, Karabinas C, Mesogitis S, Papapanagiotou A, et al. Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution. Fetal Diagn Ther. 2007;22(2):100\u20136. https:\/\/doi.org\/10.1159\/000097105.","journal-title":"Fetal Diagn Ther"},{"issue":"3","key":"1696_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5863\/1551-6776-22.3.227","volume":"22","author":"SM Groff","year":"2017","unstructured":"Groff SM, Fallatah W, Yang S, Murphy J, Crutchfield C, Marzinke M, et al. Effect of maternal obesity on maternal-fetal transfer of preoperative cefazolin at cesarean section. J Pediatr Pharmacol Ther. 2017;22(3):227\u201332. https:\/\/doi.org\/10.5863\/1551-6776-22.3.227.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1696_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejogrb.2017.01.022","volume":"210","author":"JJF Kram","year":"2017","unstructured":"Kram JJF, Greer DM, Cabrera O, Burlage R, Forgie MM, Siddiqui DS. Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section? Eur J Obstet Gynecol Reprod Biol. 2017;210:334\u201341. https:\/\/doi.org\/10.1016\/j.ejogrb.2017.01.022.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"1696_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/AOG.0000000000000789","volume":"125","author":"L Maggio","year":"2015","unstructured":"Maggio L, Nicolau DP, DaCosta M, Rouse DJ, Hughes BL. Cefazolin prophylaxis in obese women undergoing cesarean delivery. Obstet Gynecol. 2015;125(5):1205\u201310. https:\/\/doi.org\/10.1097\/AOG.0000000000000789.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"1696_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/sur.2012.040","volume":"14","author":"M Stitely","year":"2013","unstructured":"Stitely M, Sweet M, Slain D, Alons L, Holls W, Hochberg C, et al. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug. Surg Infect (Larchmt). 2013;14(5):455\u20139. https:\/\/doi.org\/10.1089\/sur.2012.040.","journal-title":"Surg Infect (Larchmt)"},{"issue":"4","key":"1696_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/AOG.0b013e31820b95e4","volume":"117","author":"L Pevzner","year":"2011","unstructured":"Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117(4):877\u201382. https:\/\/doi.org\/10.1097\/AOG.0b013e31820b95e4.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"1696_CR13","doi-asserted-by":"publisher","first-page":"415.e1","DOI":"10.1016\/j.ajog.2015.05.030","volume":"213","author":"ML Swank","year":"2015","unstructured":"Swank ML, Wing DA, Nicolau DP, McNulty JA. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol. 2015;213(3):415.e1-415.e8. https:\/\/doi.org\/10.1016\/j.ajog.2015.05.030.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1696_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1213\/ANE.0000000000004766","volume":"131","author":"VA Eley","year":"2020","unstructured":"Eley VA, Christensen R, Ryan R, Jackson D, Parker SL, Smith M, et al. Prophylactic cefazolin dosing in women with body mass index > 35 kg\u00b7m\u22122 undergoing cesarean delivery: a pharmacokinetic study of plasma and interstitial fluid. Anesth Analg. 2020;131(1):199\u2013207. https:\/\/doi.org\/10.1213\/ANE.0000000000004766.","journal-title":"Anesth Analg"},{"issue":"6","key":"1696_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/jcph.851","volume":"57","author":"M Grupper","year":"2017","unstructured":"Grupper M, Kuti JL, Swank ML, Maggio L, Hughes BL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and adipose tissue from overweight and obese women undergoing cesarean delivery. J Clin Pharmacol. 2017;57(6):712\u20139. https:\/\/doi.org\/10.1002\/jcph.851.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1696_CR16","doi-asserted-by":"publisher","first-page":"541.e1","DOI":"10.1016\/j.ajog.2015.06.034","volume":"213","author":"OM Young","year":"2015","unstructured":"Young OM, Shaik IH, Twedt R, Binstock A, Althouse AD, Venkataramanan R, et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. Am J Obstet Gynecol. 2015;213(4):541.e1-541.e7. https:\/\/doi.org\/10.1016\/j.ajog.2015.06.034.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1696_CR17","doi-asserted-by":"publisher","first-page":"170.e1","DOI":"10.1016\/j.ajog.2008.08.067","volume":"200","author":"K Allegaert","year":"2009","unstructured":"Allegaert K, van Mieghem T, Verbesselt R, de Hoon J, Rayyan M, Devlieger R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol. 2009;200(2):170.e1-170.e7. https:\/\/doi.org\/10.1016\/j.ajog.2008.08.067.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1696_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/0002-9378(90)91101-H","volume":"163","author":"CEL Brown","year":"1990","unstructured":"Brown CEL, Christmas JT, Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. Am J Obstet Gynecol. 1990;163(3):938\u201343. https:\/\/doi.org\/10.1016\/0002-9378(90)91101-H.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"1696_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0029-7844(01)01629-5","volume":"98","author":"T Fiore Mitchell","year":"2001","unstructured":"Fiore Mitchell T. Maternal and transplacental pharmacokinetics of cefazolin. Obstet Gynecol. 2001;98(6):1075\u20139. https:\/\/doi.org\/10.1016\/S0029-7844(01)01629-5.","journal-title":"Obstet Gynecol"},{"issue":"13","key":"1696_CR20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1080\/14767058.2020.1786529","volume":"35","author":"Y Fouks","year":"2022","unstructured":"Fouks Y, Ashwal E, Yogev Y, Amit S, Ben Mayor Bashi T, Sinai N, et al. Calculating the appropriate prophylactic dose of cefazolin in women undergoing cesarean delivery. J Matern Fetal Neonatal Med. 2022;35(13):2518\u201323. https:\/\/doi.org\/10.1080\/14767058.2020.1786529.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"1696_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/136.3.377","volume":"136","author":"B Bernard","year":"1977","unstructured":"Bernard B, Barton L, Abate M, Ballard CA. Maternal-fetal transfer of cefazolin in the first twenty weeks of pregnancy. J Infect Dis. 1977;136(3):377\u201382. https:\/\/doi.org\/10.1093\/infdis\/136.3.377.","journal-title":"J Infect Dis"},{"issue":"4","key":"1696_CR22","first-page":"152","volume":"3","author":"N Yamada","year":"1982","unstructured":"Yamada N, Ritschel WA, Kido K. Analog computer simulation of maternal\u2013fetal transfer of cefazolin. Int J Biol Res Pregnancy. 1982;3(4):152\u20137 (PubMed PMID: 7152713).","journal-title":"Int J Biol Res Pregnancy"},{"issue":"6","key":"1696_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1365-2710.2007.00864.x","volume":"32","author":"J Popovi\u0107","year":"2007","unstructured":"Popovi\u0107 J, Gruji\u0107 Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. J Clin Pharm Ther. 2007;32(6):595\u2013602. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00864.x.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"1696_CR24","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1093\/jac\/dkab329","volume":"76","author":"O Elkayal","year":"2021","unstructured":"Elkayal O, Allegaert K, Spriet I, Smits A, Seghaye MC, Charlier C, et al. Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates. J Antimicrob Chemother. 2021;76(12):3229\u201336. https:\/\/doi.org\/10.1093\/jac\/dkab329.","journal-title":"J Antimicrob Chemother"},{"key":"1696_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/897216","volume":"2014","author":"JGC van Hasselt","year":"2014","unstructured":"van Hasselt JGC, Allegaert K, van Calsteren K, Beijnen JH, Schellens JHM, Huitema ADR. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Res Int. 2014;2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/897216.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1696_CR26","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1128\/AAC.02613-13","volume":"58","author":"MH Elkomy","year":"2014","unstructured":"Elkomy MH, Sultan P, Drover DR, Epshtein E, Galinkin JL, Carvalho B. Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. Antimicrob Agents Chemother. 2014;58(6):3504\u201313. https:\/\/doi.org\/10.1128\/AAC.02613-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9\u201310","key":"1696_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2298\/SARH1010600G","volume":"138","author":"Z Grujic","year":"2010","unstructured":"Grujic Z, Popovic J, Bogavac M, Grujic I. Preoperative administration of cephalosporins for elective caesarean delivery. Srp Arh Celok Lek. 2010;138(9\u201310):600\u20133. https:\/\/doi.org\/10.2298\/SARH1010600G.","journal-title":"Srp Arh Celok Lek"},{"issue":"2","key":"1696_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2165\/00003088-198712020-00004","volume":"12","author":"A Philipson","year":"1987","unstructured":"Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987;12(2):136\u201344. https:\/\/doi.org\/10.2165\/00003088-198712020-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"07","key":"1696_CR29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1055\/s-0038-1673654","volume":"36","author":"SK Dotters-Katz","year":"2019","unstructured":"Dotters-Katz SK, Smid MC, Grace MR, Gunatilake RP, Sykes C, Blake K, et al. The effect of blood loss on cefazolin levels in women undergoing cesarean delivery. Am J Perinatol. 2019;36(07):688\u201394. https:\/\/doi.org\/10.1055\/s-0038-1673654.","journal-title":"Am J Perinatol"},{"issue":"7","key":"1696_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0002-9378(16)32526-1","volume":"142","author":"A Philipson","year":"1982","unstructured":"Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol. 1982;142(7):823\u20138. https:\/\/doi.org\/10.1016\/S0002-9378(16)32526-1.","journal-title":"Am J Obstet Gynecol"},{"issue":"2 Suppl","key":"1696_CR31","first-page":"613","volume":"6","author":"P Spreafico","year":"1987","unstructured":"Spreafico P, Scian A, Epis A, Vassen L, Bonazzi C, Lovotti M. Cesarean section: antibiotic prophylaxis with ceftezole. Chemioterapia. 1987;6(2 Suppl):613\u20136 (PubMed PMID: 3334648).","journal-title":"Chemioterapia"},{"issue":"4","key":"1696_CR32","first-page":"409","volume":"60","author":"P Duff","year":"1982","unstructured":"Duff P, Gibbs RS, Jorgensen JH, Alexander G. The pharmacokinetics of prophylactic antibiotics administered by intraoperative irrigation at the time of cesarean section. Obstet Gynecol. 1982;60(4):409\u201312 (PubMed PMID: 7121925).","journal-title":"Obstet Gynecol"},{"key":"1696_CR33","doi-asserted-by":"publisher","unstructured":"N\u00f6schel H, Peiker G, Voigt R, Meinhold P, M\u00fcller B, Schr\u00f6der S, Bonow A. Research on pharmacokinetics during pregnancy. Arch Toxicol Suppl. 1980;4:380-4. https:\/\/doi.org\/10.1007\/978-3-642-67729-8_83. PMID: 6933942.","DOI":"10.1007\/978-3-642-67729-8_83"},{"issue":"7","key":"1696_CR34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/0002-9378(83)91073-6","volume":"146","author":"JF Flaherty","year":"1983","unstructured":"Flaherty JF, Boswell GW, Winkel CA, Elliott JP. Pharmacokinetics of cefoxitin in patients at term gestation: lavage versus intravenous administration. Am J Obstet Gynecol. 1983;146(7):760\u20136. https:\/\/doi.org\/10.1016\/0002-9378(83)91073-6.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"1696_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/0002-9378(83)90245-4","volume":"147","author":"H Giamarellou","year":"1983","unstructured":"Giamarellou H, Gazis J, Petrikkos G, Antsaklis A, Aravantinos D, Daikos GK. A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy. Am J Obstet Gynecol. 1983;147(8):914\u20139. https:\/\/doi.org\/10.1016\/0002-9378(83)90245-4.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"1696_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/BF02219669","volume":"10","author":"AJM Roex","year":"1988","unstructured":"Roex AJM, van Loenen AC. Pharmacokinetics of three-dose cefoxitin prophylaxis in caesarean section. Pharm Weekbl. 1988;10(6):281\u20133. https:\/\/doi.org\/10.1007\/BF02219669.","journal-title":"Pharm Weekbl"},{"issue":"2","key":"1696_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1471-0528.1981.tb00959.x","volume":"88","author":"P Bousfield","year":"1981","unstructured":"Bousfield P, Browning AK, Mullinger BM, Elstein M. Cefuroxime: potential use in pregnant women at term. BJOG. 1981;88(2):146\u20139. https:\/\/doi.org\/10.1111\/j.1471-0528.1981.tb00959.x.","journal-title":"BJOG"},{"issue":"2","key":"1696_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1471-0528.1981.tb00958.x","volume":"88","author":"I Craft","year":"1981","unstructured":"Craft I, Mullinger BM, Kennedy MRK. Placental transfer of cefuroxime. BJOG. 1981;88(2):141\u20135. https:\/\/doi.org\/10.1111\/j.1471-0528.1981.tb00958.x.","journal-title":"BJOG"},{"issue":"3","key":"1696_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0028-2243(94)90278-X","volume":"54","author":"DE Holt","year":"1994","unstructured":"Holt DE, Broadbent M, Spencer JAD, de Louvois J, Hurley R, Harvey D. The placental transfer of cefuroxime at parturition. Eur J Obstet Gynecol Reprod Biol. 1994;54(3):177\u201380. https:\/\/doi.org\/10.1016\/0028-2243(94)90278-X.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"1696_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/1753-0407.12288","volume":"8","author":"M Lalic-Popovic","year":"2016","unstructured":"Lalic-Popovic M, Paunkovic J, Grujic Z, Golocorbin-Kon S, Milasinovic L, Al-Salami H, et al. Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes. J Diabetes. 2016;8(2):238\u201345. https:\/\/doi.org\/10.1111\/1753-0407.12288.","journal-title":"J Diabetes"},{"issue":"2","key":"1696_CR41","first-page":"255","volume":"81","author":"JW De Leeuw","year":"1993","unstructured":"De Leeuw JW, Roumen FJ, Bouckaert PX, Cremers HM, Vree TB. Achievement of therapeutic concentrations of cefuroxime in early preterm gestations with premature rupture of the membranes. Obstet Gynecol. 1993;81(2):255\u201360 (PubMed PMID: 8423961).","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1696_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF01967832","volume":"12","author":"FJME Roumen","year":"1990","unstructured":"Roumen FJME, Bouckaert PXJM, Cremers HMHG, Vree TB. Pharmacokinetics of cefuroxime in pregnant patients with preterm premature rupture of the membranes. Pharm Weekbl Sci. 1990;12(6):275\u20139. https:\/\/doi.org\/10.1007\/BF01967832.","journal-title":"Pharm Weekbl Sci"},{"issue":"9_suppl","key":"1696_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/00359157770700S902","volume":"70","author":"CH O\u2019callaghan","year":"1977","unstructured":"O\u2019callaghan CH, Harding SM. The pharmacokinetics of cefuroxime in man in relation to its antibacterial activity. Proc R Soc Med. 1977;70(9_suppl):4\u201310. https:\/\/doi.org\/10.1177\/00359157770700S902.","journal-title":"Proc R Soc Med"},{"issue":"4","key":"1696_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/jac\/3.4.355","volume":"3","author":"R Norrby","year":"1977","unstructured":"Norrby R, Foord RD, Hedlund P. Clinical and pharmacokinetic studies on cefuroxime. J Antimicrob Chemother. 1977;3(4):355\u201362. https:\/\/doi.org\/10.1093\/jac\/3.4.355.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1696_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jac\/5.1.87","volume":"5","author":"SM Harding","year":"1979","unstructured":"Harding SM, Eilon LA, Harris AM. Factors affecting the intramuscular absorption of cefuroxime. J Antimicrob Chemother. 1979;5(1):87\u201393. https:\/\/doi.org\/10.1093\/jac\/5.1.87.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1696_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0002-9378(88)90768-5","volume":"158","author":"S Ogita","year":"1988","unstructured":"Ogita S, Imanaka M, Matsumoto M, Oka T, Sugawa T. Transcervical amnioinfusion of antibiotics: a basic study for managing premature rupture of membranes. Am J Obstet Gynecol. 1988;158(1):23\u20137. https:\/\/doi.org\/10.1016\/0002-9378(88)90768-5.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"1696_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijantimicag.2010.03.011","volume":"36","author":"O Ozyuncu","year":"2010","unstructured":"Ozyuncu O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. Int J Antimicrob Agents. 2010;36(2):175\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.03.011.","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl A","key":"1696_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/6.suppl_A.135","volume":"6","author":"DA Kafetzis","year":"1980","unstructured":"Kafetzis DA, Lazarides CV, Siafas CA, Georgakopoulos PA, Papadatos CJ. Transfer of cefotaxime in human milk and from mother to foetus. J Antimicrob Chemother. 1980;6(suppl A):135\u201341. https:\/\/doi.org\/10.1093\/jac\/6.suppl_A.135.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1696_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1128\/AAC.16.2.127","volume":"16","author":"R L\u00fcthy","year":"1979","unstructured":"L\u00fcthy R, M\u00fcnch R, Blaser J, Bhend H, Siegenthaler W. Human pharmacology of cefotaxime (hr 756), a new cephalosporin. Antimicrob Agents Chemother. 1979;16(2):127\u201333. https:\/\/doi.org\/10.1128\/AAC.16.2.127.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1696_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0002-9378(95)90107-8","volume":"172","author":"J Nathorst-B\u00f6\u00f6s","year":"1995","unstructured":"Nathorst-B\u00f6\u00f6s J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. Am J Obstet Gynecol. 1995;172(1):163\u20136. https:\/\/doi.org\/10.1016\/0002-9378(95)90107-8.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1696_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jcph.1294","volume":"59","author":"A Dallmann","year":"2019","unstructured":"Dallmann A, van den Anker J, Pfister M, Koch G. Characterization of maternal and neonatal pharmacokinetic behavior of ceftazidime. J Clin Pharmacol. 2019;59(1):74\u201382. https:\/\/doi.org\/10.1002\/jcph.1294.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1696_CR52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S0002-9378(88)80010-3","volume":"159","author":"SJ Fortunato","year":"1988","unstructured":"Fortunato SJ, Bawdon RE, Welt SI, Swan KF. Steady-state cord and amniotic fluid ceftizoxime levels continuously surpass maternal levels. Am J Obstet Gynecol. 1988;159(3):570\u20133. https:\/\/doi.org\/10.1016\/S0002-9378(88)80010-3.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1696_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1128\/AAC.37.1.54","volume":"37","author":"P Bourget","year":"1993","unstructured":"Bourget P, Fernandez H, Quinquis V, Delouis C. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrob Agents Chemother. 1993;37(1):54\u20139. https:\/\/doi.org\/10.1128\/AAC.37.1.54.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1696_CR54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/106002809302700306","volume":"27","author":"P Bourget","year":"1993","unstructured":"Bourget P, Quinquis-Desmaris V, Fernandez H. Ceftriaxone distribution and protein binding between maternal blood and milk postpartum. Ann Pharmacother. 1993;27(3):294\u20137. https:\/\/doi.org\/10.1177\/106002809302700306.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1696_CR55","doi-asserted-by":"publisher","first-page":"S483","DOI":"10.1016\/j.ajog.2025.09.044","volume":"233","author":"L Sanchez-Ramos","year":"2026","unstructured":"Sanchez-Ramos L, Preis R, Romero R. Prophylactic antibiotics to prevent postcesarean infection: which antimicrobial, when, how, and why? Am J Obstet Gynecol. 2026;233(6):S483-503. https:\/\/doi.org\/10.1016\/j.ajog.2025.09.044.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01696-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:19:59Z","timestamp":1790684399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01696-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01696-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Daan J. Touw is an Editorial Board member of Clinical Pharmacokinetics, and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors declare no conflicts of interest related to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data can be accessed upon reasonable request through the corresponding author.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.A.E. contributed to the literature search, data analysis and writing the initial draft of the manuscript. K.R.M.F. contributed to the data-extraction, data analysis and writing the initial draft of the manuscript. F.M. contributed to the literature search, data analysis and writing the initial draft of the manuscript. E.H.V. contributed to the data analysis and writing the initial draft of the manuscript. J.R.P., L.C.N., M.N.L.H., R.L.J.W., and J.G.W.K. contributed to the study design. D.J.T. contributed to the conceptualization of the study, data analysis, and reviewing the manuscript. P.M. contributed to the conceptualization of the study, literature search, data extraction, data analysis, and writing and reviewing the manuscript.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}